A protective human monoclonal antibody targeting a conserved site of spike glycoprotein of SARS-CoV-2 Omicron variants
The ongoing COVID-19 pandemic caused by SARS-CoV-2 has caused serious damage to public health and the global economy, and one strategy to combat COVID-19 has been the development of broadly neutralizing antibodies for prophylactic and therapeutic use. The most emergency-use authorized (EUA) therapeutic monoclonal antibodies, are more likely to lose their neutralizing activities as the viral epitopes (e.g. the receptor-binding domain, RBD) within spike protein of SARS-CoV-2 they target are more prone to mutate. By contrast, the S2 subunit of spike protein, has a much lower frequency of mutation than ...















